- Research Article
66
- 10.1016/j.nmd.2019.11.002
244th ENMC international workshop: Newborn screening in spinal muscular atrophy May 10–12, 2019, Hoofdorp, The Netherlands
- Nov 09, 2019
- Neuromuscular Disorders
- Tamara Dangouloff + 19 more +19
Publications from 2021 to 2026
Showing 10 of 20 papers
244th ENMC international workshop: Newborn screening in spinal muscular atrophy May 10–12, 2019, Hoofdorp, The Netherlands
Fetal nuchal translucency in severe congenital heart defects: experiences in Northern Finland
Objective: To evaluate the performance of first-trimester measurement of fetal nuchal translucency (NT) in the detection of severe congenital heart defects (CHDs). Methods: During the study period of 1 January 2008 – 31 December 2011, NT was measured in 31,144 women as a part of voluntary first-trimester screening program for Down’s syndrome in Northern Finland. NT was measured by personnel trained on the job by the experienced staff. No certification or annual audits are required in Finland. However, the recommendation is that the examiner should perform 200 scans on average per year. Severe CHD was classified as a defect requiring surgery in the first year of life or a defect that led to the termination of the pregnancy. All severe CHDs diagnosed during the study period in Northern Finland could not be included in this study since all women did not participate in the first-trimester screening and some cases were missing important data. Results: Fourteen (17.7%) out of 79 severe CHDs were found with NT cutoff of 3.5 mm. Amongst the 79 severe CHD cases, there were 17 chromosomal abnormalities. With NT cutoffs of 2.0 and 1.5 mm the detection rates would have increased to 25.3% (n = 20) and 46.8% (n = 37). Using a randomly selected control group of 762 women with normal pregnancy outcomes, false positive rates (FPRs) were calculated. For NT cutoffs of 1.5, 2.0 and 3.5 mm, the FPRs were, 18.5, 3.3 and 0.4%, respectively. Conclusions: A greater than 3.5 mm NT measurement in the first-trimester ultrasound is an indication to suspect a fetal heart defect but its sensitivity to detect severe CHD is poor. In our study, only 17.7% of severe CHDs would have been detected with an NT cutoff of 3.5 mm.
Read moreTowards a point-of-care strip test to diagnose sickle cell anemia.
A rapid test to identify patients with sickle cell disease could have important benefits in low-resource settings. Sickle cell anemia (SCA) affects about 300,000 newborns each year, the majority of whom are born in sub-Saharan Africa. Low-cost therapies are available to treat SCA, but most countries in sub-Saharan Africa lack robust neonatal screening programs needed to identify patients in need of treatment. To address this need, we developed and evaluated a competitive lateral flow assay that identifies patients with SCA (genotype HbSS) in 15 minutes using undiluted whole blood. A small volume of blood (0.5 μL– 3 μL) is mixed with antibody-coated blue latex beads in a tube and applied to the strip. Strips are then placed in a well of running buffer and allowed to run for 10 minutes. Laboratory evaluation with samples containing different proportions of hemoglobin A (HbA) and hemoglobin S (HbS) indicated that the test should enable identification of SCA patients but not persons with sickle cell trait (SCT). We evaluated the test using 41 samples from individuals with SCA, SCT, and normal blood. With visual inspection or quantitative analysis, we found a 98% accuracy when differentiating SCA from normal and SCT samples as a group (90% sensitivity and 100% specificity for identifying SCA). This work demonstrates important steps towards making a lateral flow test for hemoglobinopathies more appropriate for point-of-care use; further work is needed before the test is appropriate for clinical use.
Read moreOP03.06: Prediction of fetal growth restriction using estimated fetal weight versus a combined screening model at 34 weeks of gestation
To explore the potential value of a third trimester screening based on estimated fetal weight centile (EFWc) versus a combined model composed by maternal characteristics, ultrasound and biochemical markers for the prediction of smallness for gestational age (SGA) and late-onset fetal growth restriction (FGR). Nested case–control study within a cohort of 1590 singleton gestations referred for third-trimester evaluation (32–36 weeks). Maternal characteristics, fetoplacental ultrasound and circulating biochemical markers [PlGF, lipocalin-2, estriol, and inhibin-A] were assessed in all women who subsequently delivered a SGA neonate (BW < 10th centile; n = 175) and in a control group (n = 875). SGA cases with a BW <3rd centile and/or abnormal uterine artery (UtA) Doppler and/or abnormal cerebroplacental ratio were classified as FGR. Logistic regression predictive models were developed for SGA and FGR, and their performance was compared to that obtain using EFWc alone. Using EFWc alone, 52% (AUC 0.82, 95% CI 0.77-0.85) and 64% (AUC 0.86 95% CI 0.81-0.91) of SGA and FGR cases were predicted at a 10% FPR, respectively. At a 10% FPR, a screening model combining maternal characteristics, EFWc, UtA Doppler, PlGF, and estriol, predicted 61% [AUC 0.86 (95% CI 0.83-0.89)] and 77% [AUC 0.92 (95% CI 0.88-0.95)] of SGA and FGR cases, respectively. The DR of a combined model for the prediction of SGA and FGR performs significantly better than that obtained using EFWc alone (p < 0.05). Supporting information can be found in the online version of this abstract Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
Read moreP04.01: Case‐control study of early‐onset pre‐eclampsia prediction during the 1<sup>st</sup> trimester of pregnancy with the DELFIA/AutoDELFIA PlGF kit
The objective of this study was to establish the early-onset pre-eclampsia prediction performance of the serum biochemical marker placenta growth factor (PlGF) during the 1st trimester of pregnancy. This was a retrospective case-control study with a sample set of 22 cases and 131 controls consisting of frozen leftover 11–13 week pregnancy serum specimens collected from a Canadian population. The cases and controls were matched based on sample storage time, gestational age, maternal ethnicity, maternal smoking status, number of fetuses and method of conception. Samples with other major pregnancy complications were excluded. The concentration of PlGF in the samples was measured with the DELFIA/AutoDELFIA PlGF kit (B055–101, PerkinElmer). The measured concentrations were transformed to MOMs by using a median equation established for the same population. MOMs were corrected based on maternal ethnicity and smoking status as suggested in a meta-analysis (Howard Cuckle, University of Leeds, personal communication). The median MOM (SD log MOM) of the control group and pre-eclampsia group were 1.08 (0.18) and 0.91 (0.19), respectively. The area under the ROC curve was 0.64 (CI 95% = 0.52–0.76) indicating statistically significant pre-eclampsia prediction performance (P = 0.011) using PlGF as a marker. The results showed that measuring PlGF in the 1st trimester with the DELFIA/AutoDELFIA PlGF kit has prediction power for early-onset pre-eclampsia. However, this marker alone is not sufficient for efficient screening. Thus PlGF is best used in combination with other biochemical and/or biophysical markers.
Read morePrenatal diagnosis of del(4)(q27q31.23), due to a maternal balanced complex chromosome rearrangement, characterized by array‐CGH
The 4q interstitial and terminal deletions have beenreported in more than 100 literature cases in associa-tion with variable clinical features (Strehle and Bantock,2003). The most frequent ones involve the breakpoints4q12q21.1, 4q31 and 4q33, while only in few reportsthere are more distal or interstitial deletions (Egger-mann
Read moreBioconjugated lanthanide luminescent helicates as multilabels for lab-on-a-chip detection of cancer biomarkers
The lanthanide binuclear helicate [Eu(2)(L(C2(CO(2)H)))(3)] is coupled to avidin to yield a luminescent bioconjugate EuB1 (Q = 9.3%, tau((5)D(0)) = 2.17 ms). MALDI/TOF mass spectrometry confirms the covalent binding of the Eu chelate and UV-visible spectroscopy allows one to determine a luminophore/protein ratio equal to 3.2. Bio-affinity assays involving the recognition of a mucin-like protein expressed on human breast cancer MCF-7 cells by a biotinylated monoclonal antibody 5D10 to which EuB1 is attached via avidin-biotin coupling demonstrate that (i) avidin activity is little affected by the coupling reaction and (ii) detection limits obtained by time-resolved (TR) luminescence with EuB1 and a commercial Eu-avidin conjugate are one order of magnitude lower than those of an organic conjugate (FITC-streptavidin). In the second part of the paper, conditions for growing MCF-7 cells in 100-200 microm wide microchannels engraved in PDMS are established; we demonstrate that EuB1 can be applied as effectively on this lab-on-a-chip device for the detection of tumour-associated antigens as on MCF-7 cells grown in normal culture vials. In order to exploit the versatility of the ligand used for self-assembling [Ln(2)(L(C2(CO(2)H)))(3)] helicates, which sensitizes the luminescence of both Eu(III) and Tb(III) ions, a dual on-chip assay is proposed in which estrogen receptors (ERs) and human epidermal growth factor receptors (Her2/neu) can be simultaneously detected on human breast cancer tissue sections. The Ln helicates are coupled to two secondary antibodies: ERs are visualized by red-emitting EuB4 using goat anti-mouse IgG and Her2/neu receptors by green-emitting TbB5 using goat anti-rabbit IgG. The fact that the assay is more than 6 times faster and requires 5 times less reactants than conventional immunohistochemical assays provides essential advantages over conventional immunohistochemistry for future clinical biomarker detection.
Read moreSynthesis of Lanthanide(III) Chelates by Using ‘Click’ Chemistry
Abstract The copper(I)‐catalyzed dipolar [2+3] cycloaddition reaction of an azide and a terminal alkyne is exploited in the preparation of various europium(III), terbium(III), and dysprosium(III) chelates (Schemes 1–3). By changing the nature of the alkyne and the azide, a wide range of chelates and biomolecule‐labeling reactants were obtained. The photophysical properties (Table) of the synthesized chelates are also discussed.
Read moreTritium in water electrolytic enrichment and liquid scintillation counting
Versatile Synthesis of MRI Contrast Agents Based on Carbon-Substituted Triazacycloalkanes
3-(4-Iodophenoxy)-tris(2-nitrobenzenesulfonyl)-1,4,7-triazacyclodecane (5a) was synthesized by a Mitsunobu reaction between pernosylated diethylenetriamine (4a) and 1,3-bis(trityloxy)propan-2-ol (2). 5a served as a key intermediate in the preparation of MRI contrast agents allowing biomolecule labeling both in solution and on solid phase. Keywords: MRI, labeling, azamacrocycle, Mitsunobu reaction
Read more